Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine.

Ellipticine is a potent antineoplastic agent exhibiting the multimodal mechanism of its action. This article reviews the mechanisms of predominant pharmacological and cytotoxic effects of ellipticine and shows the results of our laboratories indicating a novel mechanism of its action. The prevalent mechanisms of ellipticine antitumor, mutagenic and cytotoxic activities were suggested to be intercalation into DNA and inhibition of DNA topoisomerase II activity. We demonstrated a new mode of ellipticine action, formation of covalent DNA adducts mediated by its oxidation with cytochromes P450 (CYP) and peroxidases. The article reports the molecular mechanism of ellipticine oxidation by CYPs and identifies human and rat CYPs responsible for ellipticine metabolic activation and detoxication. It also presents a role of peroxidases (i.e. myeloperoxidase, cyclooxygenases, lactoperoxidase) in ellipticine oxidation leading to ellipticine-DNA adducts. The 9-hydroxy- and 7-hydroxyellipticine metabolites formed by CYPs and the major product of ellipticine oxidation by peroxidases, the dimer, in which the two ellipticine skeletons are connected via N(6) of the pyrrole ring of one ellipticine molecule and C9 in the second one, are the detoxication metabolites. On the contrary, 13-hydroxy- and 12-hydroxyellipticine, produced by ellipticine oxidation with CYPs, the latter one formed also spontaneously from another CYP- and peroxidase-mediated metabolite, ellipticine N(2)-oxide, are metabolites responsible for formation of two ellipticine-derived deoxyguanosine adducts in DNA. The results reviewed here allow us to propose species, two carbenium ions, ellipticine-13-ylium and ellipticine-12-ylium, as reactive species generating two major DNA adducts seen in vivo in rats treated with ellipticine. The study forms the basis to further predict the susceptibility of human cancers to ellipticine.

[1]  C. Paoletti,et al.  Peroxidase-catalyzed covalent binding of the antitumor drug N2-methyl-9-hydroxyellipticinium to DNA in vitro. , 1986, Biochemistry.

[2]  H. Gutzeit,et al.  Quercetin metabolism in vital and apoptotic human leukaemia cells , 2005, Biological chemistry.

[3]  G. Mathé,et al.  Data of pre-clinical and early clinical trials of acriflavine and hydroxy-methyl-ellipticine reviewed, enriched by the experience of their use for 18 months to 6 years in combinations with other HIV1 virostatics. , 1998, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[4]  B. Dörken,et al.  Induction of gene expression by 5-Aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms , 2005, Leukemia.

[5]  E. Frei,et al.  DNA adduct formation by the anticancer drug ellipticine and its hydroxy derivatives in human breast adenocarcinoma MCF-7 cells , 2004 .

[6]  S. Linder,et al.  Induction of endoplasmic reticulum stress by ellipticine plant alkaloids. , 2004, Molecular cancer therapeutics.

[7]  G. Grassy,et al.  The biooxidation of cytotoxic ellipticine derivatives: a key to structure-activity relationship studies? , 1988, Molecular pharmacology.

[8]  E. Sausville,et al.  Preclinical evaluation of 9-chloro-2-methylellipticinium acetate alone and in combination with conventional anticancer drugs for the treatment of human brain tumor xenografts , 1998, Journal of Cancer Research and Clinical Oncology.

[9]  T. Shono,et al.  Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. , 2001, Cancer research.

[10]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[11]  M. Hsu,et al.  Ellipticine increases the superhelical density of intracellular SV40 DNA by intercalation. , 1992, Nucleic acids research.

[12]  Lk Dalton,et al.  Synthesis of the tumour-inhibitory alkaloids, ellipticine, 9-methoxyellipticine, and related pyrido[4,3-b]carbazoles , 1967 .

[13]  E. Guittet,et al.  Interaction of nucleosides with antitumoural agents : 9-hydroxy-N-2-methylellipticinium acetate and 9-hydroxy-N-2-methylolivacinium acetate , 1985 .

[14]  D. Phillips,et al.  Mammary expression of xenobiotic metabolizing enzymes and their potential role in breast cancer. , 2000, Cancer research.

[15]  V. Arlt,et al.  Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes. , 2002, Biochemical pharmacology.

[16]  N. Sládek,et al.  Multienzyme-mediated stable and transient multidrug resistance and collateral sensitivity induced by xenobiotics , 1997, Cancer Chemotherapy and Pharmacology.

[17]  E. Frei,et al.  DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling , 2003, International journal of cancer.

[18]  M. Sefkow,et al.  Epothilone A-D and their thiazole-modified analogs as novel anticancer agents , 1999 .

[19]  Jiandong Chen,et al.  Rescue of mutant p53 transcription function by ellipticine , 2003, Oncogene.

[20]  E. Frei,et al.  Oxidation of an antitumor drug ellipticine by peroxidases. , 2005, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[21]  R. Weaver,et al.  Expression of xenobiotic metabolizing enzymes in breast cancer , 1993, The Journal of pathology.

[22]  J. Hudeček,et al.  The Anticancer Drug Ellipticine Forms Covalent DNA Adducts, Mediated by Human Cytochromes P450, through Metabolism to 13-Hydroxyellipticine and Ellipticine N2-Oxide , 2004, Cancer Research.

[23]  E. Sugikawa,et al.  Inhibition of p53 Protein Phosphorylation by 9‐Hydroxyellipticine: A Possible Anticancer Mechanism , 1995, Japanese journal of cancer research : Gann.

[24]  J. Masferrer,et al.  COX‐2 is expressed in human pulmonary, colonic, and mammary tumors , 2000, Cancer.

[25]  A. Smith,et al.  Alkaloids of Ochrosia elliptica Labill.1 , 1959 .

[26]  G. Barnett,et al.  Cyclooxygenase‐2 in oligodendroglial neoplasms , 2003, Cancer.

[27]  A. Tulpule,et al.  Altered regulation of P-450IA1 expression in a multidrug-resistant MCF-7 human breast cancer cell line. , 1988, The Journal of biological chemistry.

[28]  John E. Niederhuber,et al.  Current therapy in oncology , 1993 .

[29]  David Bouwman,et al.  Cytochrome p450 and glutathione transferase expression in human breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  S. Stanforth,et al.  Nucleophilic additions to fused benzimidazole N-oxides , 1999 .

[31]  P. D. Josephy,et al.  The role of peroxidase-catalyzed activation of aromatic amines in breast cancer. , 1996, Mutagenesis.

[32]  D. DeMarini,et al.  Molecular analysis of mutations induced by the intercalating agent ellipticine at the hisd3052 allele of salmonella typhimurium TA98 , 1992, Environmental and molecular mutagenesis.

[33]  M. Singh,et al.  High-field NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticine. , 1994, Biochemistry.

[34]  B. Meunier,et al.  Covalent binding of elliptinium acetate (NSC 264137) to nucleic acids of L1210 cells in culture. , 1986, Cancer research.

[35]  E. Guittet,et al.  Regio- and stereoselective alkylation at the 3′-terminal end of ribonucleotides by N-2-methyl-9-hydroxyellipticinium acetate : an antitumor agent , 1985 .

[36]  W. Isaacs,et al.  Cyclooxygenases in cancer: progress and perspective. , 2004, Cancer letters.

[37]  E. Frei,et al.  Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12‐hydroxyellipticine and 13‐hydroxyellipticine , 2007, International journal of cancer.

[38]  E. Frei,et al.  Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. , 2003, Chemical research in toxicology.

[39]  C. Paoletti,et al.  Covalent binding of the antitumor agent N2-methyl-9-hydroxy-ellipticinium acetate (NSC 264137) on RNA and poly A in vitro. , 1984, Biochemical and biophysical research communications.

[40]  G. Siest,et al.  Effect of apolipoprotein E on cell viability in a human neuroblastoma cell line: influence of oxidation and lipid-association , 2000, Neuroscience Letters.

[41]  B. Allard,et al.  Protonophoric Activity of Ellipticine and Isomers across the Energy-transducing Membrane of Mitochondria (*) , 1995, The Journal of Biological Chemistry.

[42]  P. Unger,et al.  Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. , 2000, Urology.

[43]  E. Guittet,et al.  Ribose as the preferential target for the oxidized form of elliptinium acetate in ribonucleos(t)ides. Biological activities of the resulting adducts. , 1986, Journal of medicinal chemistry.

[44]  Slobodan Petar Rendic,et al.  Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. , 1997, Drug metabolism reviews.

[45]  T. Kodama,et al.  Role of myeloperoxidase in the neutrophil-induced oxidation of low density lipoprotein as studied by myeloperoxidase-knockout mouse. , 2000, Journal of biochemistry.

[46]  E. Sugikawa,et al.  Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine. , 1999, Anticancer research.

[47]  A. Ritzén,et al.  Recent developments in the chemistry, biology and medicine of the epothilones. , 2001, Chemical communications.

[48]  J. Belehradek,et al.  DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives. , 1991, The Journal of biological chemistry.

[49]  J. Hudeček,et al.  Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - similarity between human and rat systems. , 2006, General physiology and biophysics.

[50]  C. Paoletti,et al.  Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationship. , 1992, Molecular pharmacology.

[51]  E. Frei,et al.  Monitoring of DNA adducts in humans and 32P-postlabelling methods. A review , 2004 .

[52]  B. Meunier,et al.  Peroxidase-catalyzed O-demethylation reactions. Quinone-imine formation from 9-methoxyellipticine derivatives. , 1985, The Journal of biological chemistry.

[53]  Chun-ching Lin,et al.  The mechanism of ellipticine-induced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells. , 2005, Cancer letters.

[54]  M. Lübbert,et al.  Changes of DNA methylation and chromatin structure in the human myeloperoxidase gene during myeloid differentiation. , 1991, Blood.

[55]  S. McKeown,et al.  Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. , 1999, Anti-cancer drug design.

[56]  G. Murray,et al.  Cytochrome P450 expression in tumours. , 1995, The Journal of pathology.

[57]  C. Auclair.  Multimodal action of antitumor agents on DNA: the ellipticine series. , 1987, Archives of biochemistry and biophysics.

[58]  K. Tabuchi,et al.  Expression of prostaglandin H synthase-2 in human brain tumors , 2001, Acta Neuropathologica.

[59]  M. Boyd,et al.  Anticancer specificity of some ellipticinium salts against human brain tumors in vitro. , 1994, Journal of medicinal chemistry.

[60]  W. Hung,et al.  Overexpression of cyclo-oxygenase 2 in squamous cell carcinoma of the hypopharynx. , 2002, Human pathology.

[61]  J. Lay,et al.  Lactoperoxidase-catalyzed activation of carcinogenic aromatic and heterocyclic amines. , 2004, Chemical research in toxicology.

[62]  B. Meunier,et al.  Model systems for metabolism studies. Biomimetic oxidation of acetaminophen and ellipticine derivatives with water-soluble metalloporphyrins associated to potassium monopersulfate. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[63]  N. Osheroff,et al.  Topoisomerase II Binds to Ellipticine in the Absence or Presence of DNA. , 1995, The Journal of Biological Chemistry.

[64]  H. Lynch,et al.  Psychologic Aspects of Cancer Genetic Testing: A Research Update for Clinicians , 1997 .

[65]  C. Paoletti,et al.  omicron-Quinone formation in the biochemical oxidation of the antitumor drug N2-methyl-9-hydroxyellipticinium acetate. , 1983, Journal of medicinal chemistry.

[66]  E. Frei,et al.  The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. , 2001, Biochemical pharmacology.

[67]  C. Paoletti,et al.  O-QUINONE FORMATION IN THE BIOCHEMICAL OXIDATION OF THE ANTITUMOR DRUG N2-METHYL-9-HYDROXYELLIPTICINIUM ACETATE , 1983 .